10-Q · May 15, 2026
ProKidney Corp. reported a decline in revenue and an increase in net loss in the recent quarter, with total revenue at $0 and a net loss of $42.6 million. Operational expenditures rose due to increased R&D activities,…
Earnings analysis · 10-Q
PROK earnings analysis
Filed August 10, 2026 · Our reading of the company's report
The latest report
The filing adds a material going-concern warning, stating that ProKidney’s existing cash resources of $181,564,000 will not support its anticipated operations for at least 12 months after the August 10, 2026 filing…
Read full summary
The filing adds a material going-concern warning, stating that ProKidney’s existing cash resources of $181,564,000 will not support its anticipated operations for at least 12 months after the August 10, 2026 filing date. The company also reported an accumulated deficit of $1,318,294,000 and expects significant and increasing operating losses as research, development, and clinical activities continue. The extracted filing does not include the current-quarter income statement, balance sheet detail, cash flow statement, or segment disclosures, so revenue, margin, EPS, and free-cash-flow trends cannot be independently quantified from the provided text.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Controls Remained Effective
Management concluded that disclosure controls and procedures were effective as of June 30, 2026, and reported no changes during the quarter that materially affected, or were reasonably likely to materially affect, internal control over financial reporting.
What to watch
-
New Going-Concern Warning
The company reported an accumulated deficit of $1,318,294,000 as of June 30, 2026 and cash and cash equivalents plus marketable securities of $181,564,000. Based on its current business plan, existing cash resources will not fund anticipated operations for at least the 12 months following the August 10, 2026 filing date, creating substantial doubt about going-concern status.
Management's outlook
No numeric revenue or EPS guidance was provided in the extracted filing. Management states that cash resources will not fund the anticipated level of operations for at least the 12 months following the August 10, 2026 filing date.
Earlier filings 4
10-K · March 18, 2026
ProKidney positions itself as a late‑clinical‑stage biotech focused on a first‑in‑class autologous cell therapy, rilparencel, for advanced CKD with diabetes; rilparencel is stated to be “the only cell therapy in Phase 3…
10-Q · November 10, 2025
ProKidney reported $217,000 of revenue in Q3 2025 and GAAP net loss per Class A share of $(0.12), an improvement vs. $(0.14) in Q3 2024. Operating loss narrowed to $(38,539) from $(48,973) in the prior-year quarter as…
10-Q · August 12, 2025
ProKidney reported first meaningful product revenue of $221,000 in Q2 2025 and $451,000 year-to-date, while continuing to run substantial operating losses. Total operating expenses declined to $39.93 million in Q2 2025…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.